Merck Licenses Cyclica's In-Silico Artificial Intelligence (AI) based Ligand Express Platform
Shots:
- Merck to get rights for Cyclica’s cloud-based in-silico proteome screening AI platform- Ligand Express to screen small molecule for determining polypharmacological profiles
- The focus of agreement is to discover and develop clinical candidates using AI and computational biophysics
- Ligand Express Platform is an AI based platform- used for understanding drug’s effect with captured panoramic view of protein and small molecule in form of on-targets and off-targets
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com